Analysis of secreted proteins for the study of bladder cancer cell aggressiveness

Journal of Proteome Research

Volumn 9, Issue 6, 2010, Pages 3243-3259

  Makridakis, Manousos ^a   Roubelakis, Maria G ^a   Bitsika, Vasiliki ^a   Dimuccio, Veronica ^b   Samiotaki, Martina ^c   Kossida, Sophia ^a   Panayotou, George ^c   Coleman, Jonathan ^d   Candiano, Giovanni ^b   Anagnou, Nikolaos P ^a,e   Vlahou, Antonia ^a  

^a BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^b G GASLINI INSTITUTE   (Italy)

^c BIOMEDICAL SCIENCES RESEARCH CENTER ALEXANDER FLEMING   (Greece)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

2DE; bladder cancer; proteomics; secretome; SPARC; T24

Indexed keywords

CLUSTERIN; CYSTATIN; FIBRILLIN; FIBRONECTIN; FIBULIN; INTERLEUKIN 6; OSTEONECTIN;

AGGRESSIVENESS; ARTICLE; BLADDER CANCER; CANCER CELL; CANCER CELL CULTURE; CELL COMMUNICATION; CELL INVASION; CELL LINE; CELL MOTILITY; CONTROLLED STUDY; CULTURE MEDIUM; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN SECRETION; PROTEOMICS; TWO DIMENSIONAL GEL ELECTROPHORESIS; WESTERN BLOTTING;

CELL LINE, TUMOR; CELL MOVEMENT; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; OSTEONECTIN; PROTEOME; PROTEOMICS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 77954615635     PISSN: 15353893     EISSN: 15353907     Source Type: Journal    
DOI: 10.1021/pr100189d     Document Type: Article

References (49)

1. Dinney, C. P.; McConkey, D. J.; Millikan, R. E.; Wu, X.; Bar-Eli, M.; Adam, L.; Kamat, A. M.; Siefker-Radtke, A. O.; Tuziak, T.; Sabichi, A. L.; Grossman, H. B.; Benedict, W. F.; Czerniak, B. Focus on bladder cancer. Cancer Cell 2004, 6, 111-116.
2. Crallan, R. A.; Georgopoulos, N. T.; Southgate, J. Experimental models of human bladder carcinogenesis. Carcinogenesis 2006, 27, 374-381.
3. Makridakis, M.; Gagos, S.; Petrolekas, A.; Roubelakis, M. G.; Bitsika, V.; Stravodimos, K.; Pavlakis, K.; Anagnou, N. P.; Coleman, J.; Vlahou, A. Chromosomal and proteome analysis of a new T24-based cell line model for aggressive bladder cancer. Proteomics 2009, 9, 287-298.
4. Xue, H.; Lu, B.; Lai, M. The cancer secretome: a reservoir of biomarkers. J. Transl. Med. 2008, 6, 52.
5. Chevallet, M.; Diemer, H.; Van Dorssealer, A.; Villiers, C.; Rabilloud, T. Toward a better analysis of secreted proteins: the example of the myeloid cells secretome. Proteomics 2007, 7, 1757-1770.
6. Faca, V. M.; Hanash, S. M. In-depth proteomics to define the cell surface and secretome of ovarian cancer cells and processes of protein shedding. Cancer Res. 2009, 69, 728-730.
7. Kulasingam, V.; Diamandis, E. P. Tissue culture-based breast cancer biomarker discovery platform. Int. J. Cancer 2008, 123, 2007-2012.
8. Hathout, Y. Approaches to the study of the cell secretome. Expert Rev. Proteomics 2007, 4, 239-248.
9. Kawanishi, H.; Matsui, Y.; Ito, M.; Watanabe, J.; Takahashi, T.; Nishizawa, K.; Nishiyama, H.; Kamoto, T.; Mikami, Y.; Tanaka, Y.; Jung, G.; Akiyama, H.; Nobumasa, H.; Guilford, P.; Reeve, A.; Okuno, Y.; Tsujimoto, G.; Nakamura, E.; Ogawa, O. Secreted CXCL1 is a potential mediator and marker of the tumor invasion of bladder cancer. Clin. Cancer Res. 2008, 14, 2579-2587.
10. Lin, C. Y.; Tsui, K. H.; Yu, C. C.; Yeh, C. W.; Chang, P. L.; Yung, B. Y. Searching cell-secreted proteomes for potential urinary bladder tumor markers. Proteomics 2006, 6, 4381-4389.
11. Roubelakis, M. G.; Pappa, K. I.; Bitsika, V.; Zagoura, D.; Vlahou, A.; Papadaki, H. A.; Antsaklis, A.; Anagnou, N. P. Molecular and proteomic characterization of human mesenchymal stem cells derived from amniotic fluid: comparison to bone marrow mesenchymal stem cells. Stem Cells Dev 2007, 16, 931-952.
12. Kaufmann, B.; Muller, S.; Hanisch, F. G.; Hartmann, U.; Paulsson, M.; Maurer, P.; Zaucke, F. Structural variability of BM-40/SPARC/osteonectin glycosylation: implications for collagen affinity. Glycobiology 2004, 14, 609-619.
13. Podhajcer, O. L.; Benedetti, L. G.; Girotti, M. R.; Prada, F.; Salvatierra, E.; Llera, A. S. The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host. Cancer Metastasis Rev. 2008, 27, 691-705.
14. Tjalsma, H.; Bolhuis, A.; Jongbloed, J. D.; Bron, S.; van Dijl, J. M. Signal peptide-dependent protein transport in Bacillus subtilis: a genome-based survey of the secretome. Microbiol. Mol. Biol. Rev. 2000, 64, 515-547.
15. Huang, L. J.; Chen, S. X.; Huang, Y.; Luo, W. J.; Jiang, H. H.; Hu, Q. H.; Zhang, P. F.; Yi, H. Proteomics-based identification of secreted protein dihydrodiol dehydrogenase as a novel serum markers of non-small cell lung cancer. Lung Cancer 2006, 54, 87-94.
16. Lou, X.; Xiao, T.; Zhao, K.; Wang, H.; Zheng, H.; Lin, D.; Lu, Y.; Gao, Y.; Cheng, S.; Liu, S.; Xu, N. Cathepsin D is secreted from M-BE cells: its potential role as a biomarker of lung cancer. J. Proteome Res. 2007, 6, 1083-1092.
17. Sarkissian, G.; Fergelot, P.; Lamy, P. J.; Patard, J. J.; Culine, S.; Jouin, P.; Rioux-Leclercq, N.; Darbouret, B. Identification of pro-MMP-7 as a serum marker for renal cell carcinoma by use of proteomic analysis. Clin. Chem. 2008, 54, 574-581.
18. Yamashita, R.; Fujiwara, Y.; Ikari, K.; Hamada, K.; Otomo, A.; Yasuda, K.; Noda, M.; Kaburagi, Y. Extracellular proteome of human hepatoma cell, HepG2 analyzed using two-dimensional liquid chromatography coupled with tandem mass spectrometry. Mol. Cell. Biochem. 2007, 298, 83-92.
19. Mauri, P.; Scarpa, A.; Nascimbeni, A. C.; Benazzi, L.; Parmagnani, E.; Mafficini, A.; Della Peruta, M.; Bassi, C.; Miyazaki, K.; Sorio, C. Identification of proteins released by pancreatic cancer cells by multidimensional protein identification technology: a strategy for identification of novel cancer markers. FASEB J. 2005, 19, 1125-1127.
20. Sardana, G.; Marshall, J.; Diamandis, E. P. Discovery of candidate tumor markers for prostate cancer via proteomic analysis of cell culture-conditioned medium. Clin. Chem. 2007, 53, 429-437.
21. Sardana, G.; Jung, K.; Stephan, C.; Diamandis, E. P. Proteomic analysis of conditioned media from the PC3, LNCaP, and 22Rv1 prostate cancer cell lines: discovery and validation of candidate prostate cancer biomarkers. J. Proteome Res. 2008, 7, 3329-3338.
22. Mbeunkui, F.; Metge, B. J.; Shevde, L. A.; Pannell, L. K. Identification of differentially secreted biomarkers using LC-MS/MS in isogenic cell lines representing a progression of breast cancer. J. Proteome Res. 2007, 6, 2993-3002.
23. Kulasingam, V.; Diamandis, E. P. Proteomics analysis of conditioned media from three breast cancer cell lines: a mine for biomarkers and therapeutic targets. Mol. Cell. Proteomics 2007, 6, 1997-2011.
24. Tai, I. T.; Tang, M. J. SPARC in cancer biology: its role in cancer progression and potential for therapy. Drug Resist. Updates 2008, 11, 231-246.
25. Hackel, C.; Czerniak, B.; Ayala, A. G.; Radig, K.; Roessner, A. Expression of plasminogen activators and plasminogen activator inhibitor 1 in dedifferentiated chondrosarcoma. Cancer 1997, 79, 53-58.
26. Ammar, H.; Closset, J. L. Clusterin activates survival through the phosphatidylinositol 3-kinase/Akt pathway. J. Biol. Chem. 2008, 283, 12851-12861.
27. Wu, C. C.; Chien, K. Y.; Tsang, N. M.; Chang, K. P.; Hao, S. P.; Tsao, C. H.; Chang, Y. S.; Yu, J. S. Cancer cell-secreted proteomes as a basis for searching potential tumor markers: nasopharyngeal carcinoma as a model. Proteomics 2005, 5, 3173-3182.
28. Chauhan, S. S.; Goldstein, L. J.; Gottesman, M. M. Expression of cathepsin L in human tumors. Cancer Res. 1991, 51, 1478-1481.
29. Ross, P. L.; Cheng, I.; Liu, X.; Cicek, M. S.; Carroll, P. R.; Casey, G.; Witte, J. S. Carboxypeptidase 4 gene variants and early-onset intermediate-to-high risk prostate cancer. BMC Cancer 2009, 9, 69.
30. Said, N.; Frierson, H. F., Jr.; Chernauskas, D.; Conaway, M.; Motamed, K.; Theodorescu, D. The role of SPARC in the tramp model of prostate carcinogenesis and progression. Oncogene 2009, 28, 3487-3498.
31. Arnold, S. A.; Brekken, R. A. SPARC: a matricellular regulator of tumorigenesis. J. Cell Commun. Signal. 2009, 3, 255-273.
32. Clark, C. J.; Sage, E. H. A prototypic matricellular protein in the tumor microenvironment-where there's SPARC, there's fire. J. Cell Biochem. 2008, 104, 721-732.
33. Sage, E. H.; Bassuk, J. A.; Yost, J. C.; Folkman, M. J.; Lane, T. F. Inhibition of endothelial cell proliferation by SPARC is mediated through a Ca(2+)-binding EF-hand sequence. J. Cell Biochem. 1995, 57, 127-140.
34. Goldblum, S. E.; Ding, X.; Funk, S. E.; Sage, E. H. SPARC (secreted protein acidic and rich in cysteine) regulates endothelial cell shape and barrier function. Proc. Natl. Acad. Sci. USA 1994, 91, 3448-3452.
35. Shankavaram, U. T.; DeWitt, D. L.; Funk, S. E.; Sage, E. H.; Wahl, L. M. Regulation of human monocyte matrix metalloproteinases by SPARC. J. Cell Physiol. 1997, 173, 327-334.
36. Gilles, C.; Bassuk, J. A.; Pulyaeva, H.; Sage, E. H.; Foidart, J. M.; Thompson, E. W. SPARC/osteonectin induces matrix metalloproteinase 2 activation in human breast cancer cell lines. Cancer Res. 1998, 58, 5529-5536.
37. Podgorski, I.; Linebaugh, B. E.; Koblinski, J. E.; Rudy, D. L.; Herroon, M. K.; Olive, M. B.; Sloane, B. F. Bone marrow-derived cathepsin K cleaves SPARC in bone metastasis. Am. J. Pathol. 2009, 175, 1255-1269.
38. Bradshaw, A. D.; Sage, E. H. SPARC, a matricellular protein that functions in cellular differentiation and tissue response to injury. J. Clin. Invest. 2001, 107, 1049-1054.
39. Diaz, V. M.; Hurtado, M.; Thomson, T. M.; Reventos, J.; Paciucci, R. Specific interaction of tissue-type plasminogen activator (t-PA) with annexin II on the membrane of pancreatic cancer cells activates plasminogen and promotes invasion in vitro. Gut 2004, 53, 993-1000.
40. Pallares, I.; Bonet, R.; Garcia-Castellanos, R.; Ventura, S.; Aviles, F. X.; Vendrell, J.; Gomis-Ruth, F. X. Structure of human carboxypeptidase A4 with its endogenous protein inhibitor, latexin. Proc. Natl. Acad. Sci. USA 2005, 102, 3978-3983.
41. Svatek, R. S.; Karam, J.; Karakiewicz, P. I.; Gallina, A.; Casella, R.; Roehrborn, C. G.; Shariat, S. F. Role of urinary cathepsin B and L in the detection of bladder urothelial cell carcinoma. J. Urol. 2008, 179, 478-484.
42. Staack, A.; Tolic, D.; Kristiansen, G.; Schnorr, D.; Loening, S. A.; Jung, K. Expression of cathepsins B, H, and L and their inhibitors as markers of transitional cell carcinoma of the bladder. Urology 2004, 63, 1089-1094.
43. Staack, A.; Koenig, F.; Daniltchenko, D.; Hauptmann, S.; Loening, S. A.; Schnorr, D.; Jung, K.; Cathepsins, B, H. L activities in urine of patients with transitional cell carcinoma of the bladder. Urology 2002, 59, 308-312.
44. Span, P. N.; Witjes, J. A.; Grebenchtchikov, N.; Geurts-Moespot, A.; Moonen, P. M.; Aalders, T. W.; Vriesema, J. L.; Kiemeney, L. A.; Schalken, J. A.; Sweep, F. C. Components of the plasminogen activator system and their complexes in renal cell and bladder cancer: comparison between normal and matched cancerous tissues. BJU Int. 2008, 102, 177-182.
45. Sosa, M. S.; Girotti, M. R.; Salvatierra, E.; Prada, F.; de Olmo, J. A.; Gallango, S. J.; Albar, J. P.; Podhajcer, O. L.; Llera, A. S. Proteomic analysis identified N-cadherin, clusterin, and HSP27 as mediators of SPARC (secreted protein, acidic and rich in cysteines) activity in melanoma cells. Proteomics 2007, 7, 4123-4134.
46. Orenes-Pinero, E.; Barderas, R.; Rico, D.; Casal, J. I.; Gonzalez-Pisano, D.; Navajo, J.; Algaba, F.; Piulats, J. M.; Sanchez-Carbayo, M. Serum and tissue profiling in bladder cancer combining protein and tissue arrays. J. Proteome Res. 2010, 9, 164-173.
47. Grassadonia, A.; Tinari, N.; Iurisci, I.; Piccolo, E.; Cumashi, A.; Innominato, P.; D'Egidio, M.; Natoli, C.; Piantelli, M.; Iacobelli, S. 90K (Mac-2 BP) and galectins in tumor progression and metastasis. Glycoconj. J. 2004, 19, 551-556.
48. Yamanaka, M.; Kanda, K.; Li, N. C.; Fukumori, T.; Oka, N.; Kanayama, H. O.; Kagawa, S. Analysis of the gene expression of SPARC and its prognostic value for bladder cancer. J. Urol. 2001, 166, 2495-2499.
49. Tu, C.; Ortega-Cava, C. F.; Chen, G.; Fernandes, N. D.; Cavallo-Medved, D.; Sloane, B. F.; Band, V.; Band, H. Lysosomal cathepsin B participates in the podosome-mediated extracellular matrix degradation and invasion via secreted lysosomes in v-Src fibroblasts. Cancer Res. 2008, 68, 9147-9156.